Verified Insights
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
Download Sample Pdf
MARKET INSIGHTS
Global External Beam Radiotherapy market size was valued at USD 6.2 billion in 2024 and is projected to reach USD 10.3 billion by 2031, exhibiting a CAGR of 7.5% during the forecast period.
External Beam Radiotherapy (EBRT) is a non-invasive cancer treatment method that delivers precisely targeted radiation beams from outside the body to destroy tumor cells while minimizing damage to surrounding healthy tissues. EBRT systems utilize advanced technologies including linear accelerators (LINACs) and proton therapy equipment, with key modalities such as Intensity-modulated Radiotherapy (IMRT), Image-guided Radiotherapy (IGRT), and Stereotactic Body Radiation Therapy (SBRT).
The market growth is driven by rising cancer incidence globally, with approximately 20 million new cases reported annually as of 2024, combined with technological advancements in radiation therapy systems. The increasing adoption of hypofractionated treatment regimens and growing investments in cancer care infrastructure across emerging economies are further propelling market expansion. Major industry players like Varian Medical Systems and Elekta AB continue to innovate, with recent developments including AI-powered treatment planning systems and compact proton therapy solutions enhancing market prospects.
Increasing Cancer Prevalence Worldwide
The rising incidence of cancer globally is a key driver for the external beam radiotherapy market, with approximately 19 million new cancer cases reported annually. External beam radiotherapy remains one of the most common and effective treatments for various cancers.
Technological Advancements in Radiotherapy Systems
Innovations such as proton therapy, stereotactic body radiotherapy (SBRT), and image-guided radiotherapy (IGRT) are expanding treatment capabilities. These technologies improve precision while reducing damage to surrounding healthy tissues.
The global external beam radiotherapy equipment market is projected to grow at 6.8% CAGR through 2030.
Increasing government investments in healthcare infrastructure and growing awareness about early cancer detection are further contributing to market expansion.
MARKET CHALLENGES
High Equipment and Treatment Costs
The significant capital investment required for external beam radiotherapy systems, ranging from $2-5 million per unit, creates barriers to adoption in developing regions. Maintenance and operational costs also remain substantial.
Other Challenges
Regulatory Hurdles
Stringent regulatory approvals for radiotherapy devices delay market entry of new technologies.
Workforce Shortages
There's a global shortage of qualified radiation oncologists and medical physicists to operate advanced systems.
Alternative Treatment Modalities
The availability of alternative cancer treatments including immunotherapy, targeted drug therapies, and internal radiotherapy (brachytherapy) limits market growth for external beam radiotherapy in certain cancer types.
Emerging Markets Expansion
Developing countries in Asia and Latin America present significant growth opportunities due to increasing healthcare expenditure and improving cancer care infrastructure. China and India are expected to account for nearly 35% of new installations by 2025.
Compact and Mobile Systems Development
The trend toward smaller, more affordable radiotherapy units suitable for community hospitals could expand access to treatment in underserved regions.
Segment Analysis:| Segment Category | Sub-Segments | Key Insights |
| By Type |
|
Volumetric Modulated Arc Therapy is emerging as the most advanced technique due to its precise tumor targeting capabilities while minimizing radiation exposure to surrounding healthy tissues. The market shows strong preference for IGRT and IMRT systems due to their widespread clinical adoption and proven effectiveness across multiple cancer types. |
| By Application |
|
Hospital settings dominate the application segment due to their comprehensive cancer care facilities and ability to handle complex cases. Ambulatory centers are gaining traction for their cost-effectiveness and patient convenience in treating localized cancers. Research institutes drive innovation through clinical trials of advanced radiotherapy techniques. |
| By End User |
|
Public Healthcare Institutions represent the largest end-user segment due to government funding and high patient volumes. Private oncology clinics are adopting compact radiotherapy systems to expand regional access. Academic medical centers serve as innovation hubs for developing next-generation therapies while training new radiation oncologists. |
| By Technology Development |
|
Next-generation AI-integrated Systems are driving market evolution with predictive analytics and automated treatment planning. Second-generation systems maintain strong demand for their balance of precision and affordability. The industry is shifting from conventional radiotherapy towards adaptive radiotherapy solutions that modify treatment in real-time. |
| By Service Model |
|
Hybrid Models combining equipment sales with long-term service contracts are becoming the preferred commercial approach. Vendors are offering performance-based agreements and outcome-linked pricing to enhance value propositions. The market shows increasing preference for bundled solutions that include training, maintenance, and periodic technology upgrades. |
Global External Beam Radiotherapy Market Dominated by Established Medical Technology Leaders
The external beam radiotherapy market is led by Varian Medical Systems (now part of Siemens Healthineers) and Elekta AB, which collectively hold over 60% market share. Varian's TrueBeam and Halcyon systems along with Elekta's Unity MR-Linac platform represent the cutting-edge of image-guided radiotherapy technology. The competitive landscape features a mix of large-cap medical device manufacturers and specialized radiotherapy firms competing through technological innovation in particle therapy and adaptive radiotherapy solutions.
Niche players like Ion Beam Applications (IBA) dominate the proton therapy segment, while Accuray maintains strong positions in robotic radiosurgery with its CyberKnife system. Emerging competitors from Asia, particularly Chinese manufacturers like Neusoft Medical and United Imaging Healthcare, are gaining traction in cost-sensitive markets with competitively priced linac systems meeting basic radiotherapy needs.
List of Key External Beam Radiotherapy Companies ProfiledVarian Medical Systems, Inc. (Siemens Healthineers)
Ion Beam Applications SA (IBA)
ViewRay Technologies
Mevion Medical Systems
ProNova Solutions
Hitachi, Ltd.
Mitsubishi Electric Corporation
Sumitomo Heavy Industries
Neusoft Medical Systems
Shanghai United Imaging Healthcare
Brainlab AG
The external beam radiotherapy market is experiencing rapid growth due to technological innovations such as Intensity-modulated Radiotherapy (IMRT) and Volumetric Modulated Arc Therapy. These advanced treatment modalities offer greater precision in targeting tumors while minimizing damage to surrounding healthy tissues. The global market was valued at $1.2 billion in 2024 and is projected to reach $2.15 billion by 2031, growing at a CAGR of 7.3% during the forecast period.
Other TrendsIncreasing Adoption in Ambulatory Care Settings
Ambulatory radiotherapy centers are emerging as significant end-users of external beam radiotherapy systems, accounting for 28% of the global market share. This shift is driven by the need for cost-effective cancer treatment options and patient convenience. The Asia-Pacific region shows the highest growth potential in this segment, with a projected CAGR of 9.1% through 2031.
Rising Demand for Image-guided Radiotherapy SystemsImage-guided Radiotherapy (IGRT) systems are gaining prominence, representing 32% of the total market. Leading manufacturers like Varian Medical Systems and Elekta AB are investing heavily in research and development of next-generation IGRT solutions. North America currently dominates this segment with 41% market share, though Europe is witnessing accelerated adoption with 12% year-over-year growth.
The market continues to evolve with the introduction of particle beam therapy systems, particularly in specialized cancer treatment centers. However, high equipment costs remain a significant barrier to widespread adoption, with proton therapy systems costing between $20-$50 million per unit.
Industry Consolidation Through Strategic PartnershipsThe competitive landscape is characterized by mergers and acquisitions as companies seek to expand their geographic presence and technological capabilities. The top five manufacturers currently hold 68% of the global market share, with Varian Medical Systems leading at 31%. Recent collaborations between radiotherapy equipment manufacturers and AI specialists are expected to further transform treatment planning and delivery.
Regional Analysis: External Beam Radiotherapy MarketEurope
Europe represents the second-largest market for External Beam Radiotherapy, characterized by universal healthcare systems and strong government support for cancer treatment. The region shows particular strength in stereotactic radiosurgery adoption, with Germany and France leading in advanced system installations. Stringent CE marking requirements ensure high device standards but can delay market entry. Budget constraints in public health systems sometimes limit upgrade cycles for radiotherapy equipment. Northern European countries demonstrate particularly high radiotherapy utilization rates per cancer case. Harmonization efforts through ESTRO guidelines promote standardized treatment protocols across the region.
Asia-Pacific
The Asia-Pacific region is experiencing rapid growth in radiotherapy adoption, driven by increasing healthcare expenditures and rising cancer incidence. Japan and Australia lead in technology adoption, while China and India focus on expanding basic radiotherapy access. Proton therapy centers are being established across major cities, though cost remains prohibitive for most patients. Local manufacturers are gaining market share with cost-competitive systems, challenging established global players. Government initiatives to improve cancer care infrastructure are accelerating market growth, though uneven distribution of radiotherapy resources persists between urban and rural areas. The region presents significant potential for future system installations as healthcare systems modernize.
South America
South America's radiotherapy market is developing, with Brazil and Argentina accounting for the majority of advanced system installations. Limited public healthcare budgets constrain technology adoption rates, though private hospitals in major cities offer advanced treatments. Purchases are often facilitated through international funding programs and equipment leasing arrangements. Economic volatility impacts long-term equipment upgrade plans. Growing training initiatives through partnerships with North American and European institutions aim to address workforce shortage issues. The region presents significant unmet clinical needs as cancer rates rise and access to radiotherapy remains limited outside major metropolitan areas.
Middle East & Africa
The Middle East demonstrates growing radiotherapy capabilities, particularly in Gulf Cooperation Council countries investing heavily in healthcare infrastructure. Several proton therapy projects are underway in premium healthcare markets like UAE and Saudi Arabia. Sub-Saharan Africa faces severe radiotherapy access challenges, with many countries having very limited treatment capacity. International aid programs and public-private partnerships help increase basic LINAC installations in urban centers. The region shows extreme disparities in cancer treatment capabilities, with some patients traveling internationally for advanced radiotherapy unavailable locally.
This market research report offers a holistic overview of global and regional markets for the forecast period 20252032. It presents accurate and actionable insights based on a blend of primary and secondary research.
Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
Stakeholder Insights
This report is designed to support strategic decision-making for a wide range of stakeholders, including:
Pharmaceutical and biotech companies
Medical device and diagnostics manufacturers
Healthcare providers and hospital systems
Contract research and manufacturing organizations
Investors, consultants, and policy makers
-> Global External Beam Radiotherapy market was valued at USD 6.2 billion in 2024 and is projected to reach USD 10.3 billion by 2031.
Which key companies operate in Global External Beam Radiotherapy Market?
-> Key players include Varian Medical Systems, Elekta AB, Accuray Incorporated, and Ion Beam Applications, among others.
-> Key growth drivers include rising cancer incidence, technological advancements in radiation therapy, and increasing adoption of hypofractionated treatments.
-> North America holds the largest market share, while Asia-Pacific is emerging as the fastest-growing region.
-> Emerging trends include AI-powered treatment planning systems, compact proton therapy solutions, and advanced radiotherapy modalities.
“The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.”
“We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.”
“I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.”
“Their custom report on clinical trial trends was a helpful reference as we explored new indications."
“As someone working on early product planning, I found their therapeutic area briefs quite useful. The information was presented in a way that made it easy to extract key takeaways.”
“We didn’t need anything overly complex—just solid, dependable data. 24LifeScience delivered exactly that, without unnecessary fluff.”
“Their reports gave us a good foundation to start our own market assessment. While we supplemented it with other data, this was a great starting point.”
“I’ve used a few of their reports for academic and grant writing purposes. They’re generally well-cited and reliable for understanding market scope.”
At 24LifeScience, we combine domain expertise with dependable research delivery. What truly differentiates us isn't just what we do — it's how we do it. Our clients trust us because we offer consistency, security, value, and most importantly, insight that drives action.
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
We uphold rigorous data validation processes to ensure every report is reliable, up-to-date, and based on credible sources.
24LifeScience powers research for top firms in 20+ nations.Chosen by leading life sciences companies worldwide.
We offer competitive pricing models that align with your project scope — no hidden charges, no lock-in. Tailored pricing for every scale and need.
8–10+ years of life sciences expertise turned into strategic insights.We don’t just summarize data we contextualize it.
Whether it's a ready-made report or a custom project, we deliver within the promised timeline With real-time updates